REG - Haleon PLC - Appointment of Dawn Allen as CFO

HALEONAnnouncement

24/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240424:nRSX7727La&default-theme=true

RNS Number : 7727L  Haleon PLC  24 April 2024

 

 

Haleon plc: Appointment of Dawn Allen as Chief Financial Officer

 

24 April 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces the appointment of Dawn Allen as Chief Financial Officer ("CFO").
Dawn will join Haleon on 28 October 2024 and will assume the role of CFO and
join the Board from 1 November 2024.

 

This appointment follows Tobias Hestler informing the Board of his decision to
step down from his position as CFO to better balance work demands with the
management of a long-term health condition. Tobias will step down from the
Board on 1 November 2024 and will remain within the business until the end of
the year in order to ensure an orderly transition.

 

Dawn is currently the CFO at Tate & Lyle plc. Prior to joining Tate &
Lyle, Dawn had a 25-year career at Mars Inc., where she was most recently
Global CFO and VP Global Transformation. Before that, she held a number of
senior financial roles in Europe and the US. Dawn also currently serves as a
Non-Executive Director and member of the Audit and Risk Committee of ITV plc.

 

Brian McNamara, Haleon's Chief Executive Officer commented: "We are delighted
to have appointed Dawn as our next CFO. She has a proven track record as a CFO
with extensive consumer and international experience and will be a great
addition to our executive team. I want to take this opportunity to thank
Tobias for his significant contribution in creating Haleon as a standalone
business and for the close partnership over the last few years. He has played
a critical role in shaping and building Haleon's foundations and putting us on
a path for long-term success."

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would
like to thank Tobias for his significant input to the Board and his strong
support to Brian and the management team and wish him all the very best for
the future. We are very pleased to appoint Dawn as Haleon's CFO. Dawn has deep
consumer and financial experience and will be a very welcome addition to the
Board."

 

Dawn Allen commented: "I am very excited to join the team at Haleon. Its clear
purpose and fascinating journey through separation and beyond sets a strong
foundation for the future. I am looking forward to help shape the next phase
of the journey."

 

Tobias Hestler commented: "I have been a Type 1 diabetic all my life and it's
a condition that has always needed careful management. That becomes even more
important as you get older and I've therefore concluded that after 30 years,
now is the right time to step down and take my experience into non-executive
and advisory roles. I've had 15 fantastic years helping bring together the
businesses that Haleon has become and listing the company. I'm very proud of
the business we have built and the potential that it has. I will continue at
Haleon until the end of this year and look forward to helping ensure an
orderly transition to Dawn as she takes on the role."

 

Haleon also separately announces today the appointment of Line De Decker as
Chief Human Resources Officer. With over 27 years' experience, Line is
currently Chief People & Sustainability Officer at Aliaxis. Prior to that,
she held roles at GSK and DuPont, having started her career at PWC. Line will
join Haleon on 1 August 2024.

 

 

 Enquiries

 Investors                                                                       Media

 Sonya Ghobrial                          +44 7392 784784                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Nidaa Lone                           +44 7841 400607
 Emma White                              +44 7792 750133

 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

Notes to Editors

 

Biography

Dawn Allen

Dawn Allen started her career in 1991 working for the auditing firm EY based
in the UK. In 1995, she joined Courtaulds plc in their Corporate Finance
department before moving to Mars Inc., in 1997 initially to work as Europe
Confectionary Finance Manager spending some time based in the Netherlands.
She returned to the UK in 2000 taking on Sales Finance and Financial
Controller roles before being appointed as Country CFO Mars Chocolate UK in
2007.

 

In 2013 she moved to the USA to act as Regional CFO Wrigley Americas before
moving back to London in 2016 to take on the role of Global Divisional CFO,
Food, Drinks and Multisales. Then, in 2020, she was appointed as Global CFO
& VP, Global Transformation at Mars. In May 2022, Dawn was appointed CFO
of Tate & Lyle plc.

 

Dawn was appointed as a Non-Executive Director and member of the Audit &
Risk Committee of ITV plc in October 2023. Dawn was previously a Non-Executive
Director of Tasty Bite Eatables Ltd, a public company based in India. She
holds a Bachelor of Science in Chemistry at Bath University, UK, and is a
member of the Institute of Chartered Accountants of England and Wales.

 

There is no further information to be disclosed in respect of paragraph
9.6.13R of the UK Listing Rules.

 

Remuneration Statement

Dawn Allen

Dawn's remuneration arrangements on appointment have been set in accordance
with the Haleon Directors' Remuneration Policy approved by shareholders at the
2023 AGM on 20 April 2023 and will include:

 

 ●    Annual salary of £730,000;
 ●    Benefits and pension contributions in line with the Directors' Remuneration
      Policy (and aligned with the majority of the wider UK workforce);
 ●    Provisions relating to annual bonus and long-term incentive plans: a maximum
      AIP opportunity of 200% of annual salary and a maximum PSP award of 350% of
      annual salary; and
 ●    A pro-rated 2024 PSP award to reflect her start date of 28 October 2024.

 

All incentive awards are subject to malus and clawback provisions.

 

Dawn will receive replacement awards to compensate the loss of incentive
payments from her current employment. These awards remain subject to
performance conditions where appropriate and will mirror, as closely as
possible, the value, terms and release timeline of the forfeited awards.

 

Tobias Hestler

As required by section 430(2B) of the Companies Act 2006, details of
remuneration payments made or to be made to Tobias on stepping down as a
Director of the Company are detailed below.

 

Tobias's remuneration arrangements in respect of his departure have been
determined by the Remuneration Committee in line with the Directors'
Remuneration Policy.

 

Tobias will continue to receive his salary, pension and benefits until he
leaves the business on 31 December 2024. Thereafter, he will be paid in lieu
of notice for the remainder of his 12-month notice period until 23 April 2025.
A capped contribution will be made to legal fees.

 

He will be considered an eligible leaver and, in accordance with the
Directors' Remuneration Policy, will be eligible for a 2024 annual incentive
award to be determined by the Remuneration Committee in February 2025 and paid
in March 2025, with 50% deferred for three years.

 

Outstanding deferred bonus awards will be released on the original timetable,
subject to malus and clawback provisions.

 

Outstanding long-term incentive awards will be pro-rated to the end of
Tobias's employment and will vest in line with the original vesting dates,
subject to satisfaction of the performance conditions.

 

All outstanding awards will remain subject to malus and clawback provisions.
His 2024 PSP award which was granted in March 2024 will lapse.

 

Tobias's shareholding will be subject to the share ownership guideline (350%
of his current salary or, if lower, his shareholding at the time of
termination) for a period of two years after the termination of his
employment.

 

Full remuneration arrangements for the outgoing and the incoming CFO will be
disclosed in the Annual Report and Form-20F 2024 and subsequent years as
appropriate.

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQKNBKDBKBQQB